Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx Group (MDXG) Research & Development: 2011-2025

Historic Research & Development for Mimedx Group (MDXG) over the last 15 years, with Sep 2025 value amounting to $3.7 million.

  • Mimedx Group's Research & Development rose 26.90% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 24.11%. This contributed to the annual value of $12.3 million for FY2024, which is 2.56% down from last year.
  • As of Q3 2025, Mimedx Group's Research & Development stood at $3.7 million, which was up 12.11% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx Group's Research & Development peaked at $6.0 million during Q1 2022, and registered a low of -$4.7 million during Q4 2022.
  • Over the past 3 years, Mimedx Group's median Research & Development value was $3.3 million (recorded in 2025), while the average stood at $3.2 million.
  • Per our database at Business Quant, Mimedx Group's Research & Development tumbled by 182.64% in 2021 and then surged by 151.46% in 2023.
  • Mimedx Group's Research & Development (Quarterly) stood at -$2.8 million in 2021, then plummeted by 66.60% to -$4.7 million in 2022, then spiked by 151.46% to $2.4 million in 2023, then surged by 46.77% to $3.6 million in 2024, then rose by 26.90% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q3 2025, $3.3 million for Q2 2025, and $3.3 million during Q1 2025.